Merck update telcagepant with MK-3207 clinical development program
Merck update telcagepant (MK-0974) and MK-3207 clinical development program, which is an oral calcitonin gene-related peptide receptor antagonist treatment of acute migraine. MRK telcagepant current review of clinical data, telcagepant ongoing Phase III experiment. In addition, MRK termination MK-3207 clinical development program will not start phase IIb / III experiment.
Merck update telcagepant with MK-3207 clinical development program
ReplyDeleteMerck update telcagepant (MK-0974) and MK-3207 clinical development program, which is an oral calcitonin gene-related peptide receptor antagonist treatment of acute migraine. MRK telcagepant current review of clinical data, telcagepant ongoing Phase III experiment. In addition, MRK termination MK-3207 clinical development program will not start phase IIb / III experiment.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Sumanirole maleate
Quetiapine fumarate
SB-277011
Pramipexole dihydrochloride
Org 27569
LY341495
Dapagliflozin
Naltrexone
Tapentadol hydrochloride
Vorinostat